Literature DB >> 22642402

Markers of coagulation, fibrinolysis and inflammation in relation to post-thrombotic syndrome.

A C Bouman1, J J M Smits, H Ten Cate, A J Ten Cate-Hoek.   

Abstract

BACKGROUND: Post-thrombotic syndrome (PTS) occurs in 20-50% of patients after a deep venous thrombosis (DVT). It is difficult to accurately predict which patients will develop PTS. Biomarkers could be a valuable tool for PTS risk assessment.
OBJECTIVES: To investigate whether increased levels of factor (F)VIII, C-reactive protein (CRP) or D-dimer, over time, are associated with the development of PTS in patients after an acute DVT.
METHODS: PTS status was assessed using the Villalta scale. Blood sampling was performed at three points during follow-up.
RESULTS: A cohort of 228 consecutive patients was included after an acute DVT. At T1 (12 months after index DVT), both levels of D-dimer (median 725 ng mL(-1) [interquartile range, IQR 400-1400[ vs. 378 ng mL(-1) [251-652] P=0.004) and CRP (median 3.9 mg L(-1) [IQR 1.6-8.5] vs. 2.4 mg L(-1) [1.0-4.3] P=0.018) were increased in patients with PTS, compared with patients without PTS. Factor (F)VIII was not associated with PTS. In the multivariate logistic regression analysis, varicosities (odds ratio [OR] 13.4 95% confidence interval [CI] 3.0-59.1 P=0.001), a previous ipsilateral DVT (OR 6.3 95% CI 1.5-26.9 P=0.012) and CRP>5 mg L(-1) on T1 (OR 8.0 95% CI 2.4-26.4 P=0.001) were significantly associated with PTS.
CONCLUSIONS: Besides previous ipsilateral DVT and varicosities, CRP>5 mg L(-1) at T1 was strongly and independently associated with PTS. Persistent inflammation rather than hypercoagulability might be the most important etiological factor in PTS, and may be a target for future therapy. The development of a risk score for PTS, including both clinical risk factors and biomarker levels, such as CRP, might be desirable.
© 2012 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22642402     DOI: 10.1111/j.1538-7836.2012.04798.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  19 in total

Review 1.  Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.

Authors:  Richard Kones
Journal:  Vasc Health Risk Manag       Date:  2013-10-21

2.  Plasma fibrinolysis, inflammatory markers, and postthrombotic syndrome: preliminary findings from the Kids-DOTT Biobank.

Authors:  Marisol Betensky; Ernest K Amankwah; Stephanie Brandal; Allen D Everett; Neil A Goldenberg
Journal:  Blood Adv       Date:  2021-01-12

3.  Value of platelet indices in identifying complete resolution of thrombus in deep venous thrombosis patients.

Authors:  Utkan Sevuk; Rojhat Altindag; Mehmet Veysi Bahadir; Nurettin Ay; Ertan Demirtas; Fırat Ayaz
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-02       Impact factor: 0.900

4.  The post-thrombotic syndrome: a 2012 therapeutic update.

Authors:  Jean-Philippe Galanaud; Susan R Kahn
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-04

5.  Plasma MMP and TIMP evaluation in patients with deep venous thrombosis: could they have a predictive role in the development of post-thrombotic syndrome?

Authors:  Stefano de Franciscis; Luca Gallelli; Bruno Amato; Lucia Butrico; Alessio Rossi; Gianluca Buffone; Francesco G Caliò; Giovanni De Caridi; Raffaele Grande; Raffaele Serra
Journal:  Int Wound J       Date:  2015-09-24       Impact factor: 3.315

6.  18F-fluorodeoxyglucose positron emission tomography/computed tomography enables the detection of recurrent same-site deep vein thrombosis by illuminating recently formed, neutrophil-rich thrombus.

Authors:  Tetsuya Hara; Jessica Truelove; Ahmed Tawakol; Gregory R Wojtkiewicz; William J Hucker; Megan H MacNabb; Anna-Liisa Brownell; Kimmo Jokivarsi; Chase W Kessinger; Michael R Jaff; Peter K Henke; Ralph Weissleder; Farouc A Jaffer
Journal:  Circulation       Date:  2014-07-28       Impact factor: 29.690

7.  Pediatric May-Thurner Syndrome-Systematic review and individual patient data meta-analysis.

Authors:  Laura Avila; Noelle Cullinan; Michael White; Marian Gaballah; Anne Marie Cahill; Deepti Warad; Vilmarie Rodriguez; Cristina Tarango; Anna Hoppmann; Stephen Nelson; Tomas Kuhn; Tina Biss; Aaron Weiss; Michael Temple; João G Amaral; Nour Amiri; Ana C Xavier; Samuele Renzi; Leonardo R Brandão
Journal:  J Thromb Haemost       Date:  2021-04-01       Impact factor: 5.824

8.  Gene microarray analyses for potential biomarkers of single and recurrent venous thromboembolism.

Authors:  Wugang Zhou; Ke Zhang; Dongrui Chen; Pingjin Gao; Qiao Wang
Journal:  Mol Med Rep       Date:  2015-09-22       Impact factor: 2.952

Review 9.  Guidance for the prevention and treatment of the post-thrombotic syndrome.

Authors:  Susan R Kahn; Jean-Philippe Galanaud; Suresh Vedantham; Jeffrey S Ginsberg
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

Review 10.  Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence.

Authors:  Anetta Undas
Journal:  Biomed Res Int       Date:  2017-06-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.